FDA Designates Eltoprazine Orphan Drug in Parkinson's Disease


Amarantus BioScience announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).

In Febraury 2015, the Company announced positive data for eltoprazine from a Phase 2 initial proof-of-concept clinical study and published the results in the journal Brain. Two additional independent peer-reviewed scientific publications highlighted eltoprazine and its mechanism of action for the treatment of PD-LID.

RELATED: Efficacy of Physical Therapy for Parkinson's Questioned in Study

Eltoprazine is a small molecule 5HT1A/1B partial agonist currently under investigation for the treatment of PD-LID, adult attention deficit hyperactivity disorder (ADHD), and Alzheimer's aggression.

For more information visit Amarantus.com.